These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 33677771)

  • 1. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.
    Chen S; Zhou J; Wu X; Meng T; Wang B; Liu H; Wang T; Zhao X; Kong Y; Wu S; Ou X; Jia J; Sun Y; You H
    Hepatol Int; 2021 Jun; 15(3):611-620. PubMed ID: 33677771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M
    Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS; van Campenhout MJH; Xie Q; Brouwer WP; Chi H; Qi X; Chen L; Tabak F; Hansen BE; Janssen HLA
    Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
    J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.
    He Y; Zhou Y; Wang H; Peng X; Chang Y; Hu P; Ren H; Xu H
    BMC Pediatr; 2022 Jul; 22(1):426. PubMed ID: 35854256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD; Chen XP; Chen R; Chen XF; Huang J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z; Zhou F; Zhou Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):878-81. PubMed ID: 23803202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study.
    Han M; Jiang J; Hou J; Tan D; Sun Y; Zhao M; Ning Q
    Antivir Ther; 2016; 21(4):337-44. PubMed ID: 26734984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
    BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
    Brouwer WP; Xie Q; Sonneveld MJ; Zhang N; Zhang Q; Tabak F; Streinu-Cercel A; Wang JY; Idilman R; Reesink HW; Diculescu M; Simon K; Voiculescu M; Akdogan M; Mazur W; Reijnders JG; Verhey E; Hansen BE; Janssen HL;
    Hepatology; 2015 May; 61(5):1512-22. PubMed ID: 25348661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
    Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.